Mersana Therapeutics, Inc. Business Operations Contracts & Agreements
21 Contracts & Agreements
- Collaboration Agreements (17 contracts)
- Indemnification Agreements (1)
- Sales Agreements (3)
- Sales Agreement, dated February 28, 2024, by and between the Company and Cowen and Company, LLC (Filed With SEC on February 28, 2024)
- Amendment No. 1 to the Research Collaboration and License Agreement (effective February 2, 2022), dated July 14, 2023, by and between Mersana Therapeutics, Inc. and Janssen... (Filed With SEC on November 7, 2023)
- Amendment 3 to the Collaboration and Commercial License Agreement, dated February 28, 2017, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on May 9, 2023)
- Amendment 2 to the Collaboration and Commercial License Agreement, dated August 12, 2016, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on May 9, 2023)
- Amendment 1 to the Collaboration and Commercial License Agreement, dated June 1, 2016, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on May 9, 2023)
- Collaboration and Commercial License Agreement, dated June 23, 2014, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on May 9, 2023)
- Collaboration and Commercial License Agreement, dated December 22, 2022, between Mersana Therapeutics, Inc. and Ares Trading S.A (Filed With SEC on February 28, 2023)
- Sales Agreement dated November 7, 2022 by and between the Company and Cowen and Company, LLC (Filed With SEC on November 7, 2022)
- Research Collaboration and License Agreement, dated February 2, 2022, between the Company and Janssen Biotech, Inc (Filed With SEC on May 9, 2022)
- Sales Agreement dated February 28, 2022 by and between the Company and Cowen and Company, LLC (Filed With SEC on February 28, 2022)
- Amendment 4 to Collaboration and Commercial License Agreement dated May 15, 2018, by and between Mersana Therapeutics, Inc. and Merck KGaA (Filed With SEC on August 14, 2018)
- Third Amendment to Amended and Restated Research Collaboration and Commercial License Agreement, dated October 30, 2017, by and between Mersana Therapeutics, Inc. and Millennium... (Filed With SEC on November 13, 2017)
- SECOND AMENDMENT TO AMENDED AND RESTATED RESEARCH COLLABORATION AND COMMERCIAL LICENSE AGREEMENT (Filed With SEC on August 11, 2017)
- MERSANA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on June 16, 2017)
- CONFIDENTIAL AMENDMENT NUMBER ONE to the COLLABORATION AGREEMENT (Filed With SEC on June 1, 2017)
- CONFIDENTIAL AMENDMENT NUMBER ONE to the COLLABORATION AGREEMENT (Filed With SEC on June 1, 2017)
- CONFIDENTIAL COLLABORATION AGREEMENT BY AND BETWEEN ADIMAB, LLC AND MERSANA THERAPEUTICS, INC. JULY 25, 2012 [***] Portions of this exhibit have been redacted pursuant to a... (Filed With SEC on June 1, 2017)
- CONFIDENTIAL AMENDMENT 3 TO COLLABORATION AND COMMERCIAL LICENSE AGREEMENT (Filed With SEC on June 1, 2017)
- CONFIDENTIAL AMENDMENT 2 TO COLLABORATION AND COMMERCIAL LICENSE AGREEMENT (Filed With SEC on June 1, 2017)
- CONFIDENTIAL AMENDMENT 1 TO COLLABORATION AND COMMERCIAL LICENSE AGREEMENT (Filed With SEC on June 1, 2017)
- CONFIDENTIAL COLLABORATION AND COMMERCIAL LICENSE AGREEMENT between MERSANA THERAPEUTICS, INC. and MERCK KGaA (Filed With SEC on June 1, 2017)
